Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)

Trial Profile

A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mizacorat (Primary) ; Prednisolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 05 Jun 2021 Primary endpoint has not been met. (Change from baseline in 28 joint Disease Activity Score using CRP (DAS 28 - CRP) at day 15 according to result presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 05 Jun 2021 Results assessing efficacy, safety and tolerability of AZD9567 with prednisolone in patients with active rheumatoid arthritis (RA), presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top